Speculatively Bullish Options Activity in Mylan (MYL) -Susquehanna

Mylan (MYL) & Biocon Ltd. Presented New Clinical Data on Insulin Glargine Program at ADA Meetings

June 12, 2017 5:55 AM EDT

Mylan N.V. (NASDAQ: MYL) and Biocon Ltd. today announced the presentation of new data from the insulin glargine clinical program, including the INSTRIDE studies at the American Diabetes Association's 77th Scientific Sessions in San Diego. The studies confirmed the efficacy, safety and immunogenicity of MYL-1501D, insulin glargine, in comparison to Lantus® in patients with Type 1 and Type 2 diabetes. Data demonstrating pharmacokinetic and pharmacodynamic equivalence also was presented.

Insulin glargine is a long-acting insulin used to treat adults with Type 2 diabetes, as well as... More

Small is lucrative for Wachtell, corporate America's legal defense force

June 8, 2017 4:45 AM EDT

By Greg Roumeliotis

NEW YORK (Reuters) - Every Tuesday, partners and associates at Wachtell, Lipton, Rosen & Katz gather for a communal lunch in the dining room of the law firm's Manhattan offices.

Food ordered from top New York restaurants is served, but the real attraction is Martin Lipton, one of the firm's co-founders and corporate America's most famous consigliere.

The father of the 'poison pill' a key defense strategy used against hostile takeovers Lipton has helped build the firm into the most lucrative legal outfit in the world, a go-to shop for companies seeking to seal... More

Mylan defends chairman to ISS ahead of June 22 investor vote

June 7, 2017 10:42 AM EDT

(Reuters) - Mylan NV (NASDAQ: MYL) defended Chairman Robert Coury's role to ISS this week as the influential proxy firm prepares to advise shareholders on how they should vote on the re-election of Coury and other directors, according to a letter the drugmaker released on Wednesday.

New York City and State pension funds and the California Teachers' Retirement System are urging shareholders to vote on June 22 against Coury and five other directors. The funds cite the board's poor oversight of Coury's high pay package, investigations into how much it charged the government and... More